KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02 2024 - 6:30AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that the compensation committee of KalVista’s board of directors
granted twelve newly-hired employees inducement options to purchase
an aggregate of 84,000 shares of KalVista common stock on July 1,
2024 as inducements material to each employee entering into
employment with KalVista. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $11.89 per share, which
was equal to the closing price of KalVista common stock on the
grant date. One-fourth of the options vest on the one-year
anniversary of the vesting commencement date and the remainder vest
in equal monthly installments over the next three years, in each
case subject to the new employee’s continued service with the
company. Each stock option has a 10-year term and is subject to the
terms and conditions of KalVista’s Inducement Equity Incentive Plan
and a stock option agreement covering the grant.
About KalVista Pharmaceuticals, Inc. KalVista
Pharmaceuticals, Inc. is a global pharmaceutical company focused on
the development and delivery of oral medicines for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024 and submitted an NDA with the FDA in
June 2024. KalVista expects to file for approval in the UK, Europe,
and Japan later in 2024.
For more information about KalVista, please visit
www.kalvista.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702602098/en/
KalVista Pharmaceuticals, Inc.
Jarrod Aldom Vice President, Corporate Communications (201)
705-0254 jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Jun 2024 to Jul 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Jul 2023 to Jul 2024